| HLA-B* 5701 screening for hypersensitivity to abacavir S Mallal, E Phillips, G Carosi, JM Molina, C Workman, J Tomažič, ... New England Journal of Medicine 358 (6), 568-579, 2008 | 2147 | 2008 |
| Class of antiretroviral drugs and the risk of myocardial infarction DAD Study Group New England Journal of Medicine 356 (17), 1723-1735, 2007 | 1830 | 2007 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1497 | 2006 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1171 | 2008 |
| Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, ... New England Journal of Medicine 369 (19), 1807-1818, 2013 | 1017 | 2013 |
| Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority … P Cahn, AL Pozniak, H Mingrone, A Shuldyakov, C Brites, ... The Lancet 382 (9893), 700-708, 2013 | 600 | 2013 |
| Subcutaneous REGEN-COV antibody combination to prevent Covid-19 MP O’Brien, E Forleo-Neto, BJ Musser, F Isa, KC Chan, N Sarkar, KJ Bar, ... New England Journal of Medicine 385 (13), 1184-1195, 2021 | 463 | 2021 |
| Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ... Annals of internal medicine 165 (9), 625-634, 2016 | 422 | 2016 |
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes B Ledergerber The Lancet 364 (9428), 51-62, 2004 | 391 | 2004 |
| The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D: A: D study MG Law, N Friis‐Møller, WM El‐Sadr, R Weber, P Reiss, ... HIV medicine 7 (4), 218-230, 2006 | 385 | 2006 |
| Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America Antiretroviral Therapy Cohort Collaboration Clinical Infectious Diseases 41 (12), 1772-1782, 2005 | 287 | 2005 |
| A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis RF Betts, M Nucci, D Talwar, M Gareca, F Queiroz-Telles, RJ Bedimo, ... Clinical infectious diseases 48 (12), 1676-1684, 2009 | 248 | 2009 |
| Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program Mind Exchange Working Group, A Antinori, G Arendt, I Grant, S Letendre, ... Clinical Infectious Diseases 56 (7), 1004-1017, 2013 | 225 | 2013 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 214 | 2018 |
| Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) WP Brouwer, Q Xie, MJ Sonneveld, N Zhang, Q Zhang, F Tabak, ... Hepatology 61 (5), 1512-1522, 2015 | 210 | 2015 |
| Fostemsavir in adults with multidrug-resistant HIV-1 infection M Kozal, J Aberg, G Pialoux, P Cahn, M Thompson, JM Molina, ... New England Journal of Medicine 382 (13), 1232-1243, 2020 | 154 | 2020 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 103 | 2022 |
| JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection F Zoulim, O Lenz, JJ Vandenbossche, W Talloen, T Verbinnen, I Moscalu, ... Gastroenterology 159 (2), 521-533. e9, 2020 | 101 | 2020 |
| Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials GJ Dore, B Conway, Y Luo, E Janczewska, B Knysz, Y Liu, ... Journal of hepatology 64 (1), 19-28, 2016 | 100 | 2016 |
| Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection J McHutchison, Z Goodman, K Patel, H Makhlouf, M Rodriguez–Torres, ... Gastroenterology 138 (4), 1365-1373. e2, 2010 | 100 | 2010 |
